

Intraarticular application of autologous conditioned serum (ACS) reduces bone tunnel widening after ACL reconstructive surgery in a randomized controlled trial

Nikica Darabos · Miroslav Haspl · Carsten Moser ·
Anela Darabos · Dubravka Bartolek ·
Dietrich Groenemeyer

Received: 25 July 2010 / Accepted: 14 February 2011
© Springer-Verlag 2011

Abstract

Purpose Pro-inflammatory cytokines play a pivotal role in osteoarthritis, as well as in bone tunnel widening after ACL reconstructive surgery. A new treatment option is to administer autologous conditioned serum (ACS) containing endogenous anti-inflammatory cytokines including IL-1Ra and growth factors (IGF-1, PDGF, and TGF- β 1, among others) in the liquid blood phase. The purpose of this trial was to establish whether the postoperative outcome could be affected by intraarticular application of ACS.

Methods In a prospective, randomized, double-blinded, placebo-controlled trial with two parallel groups, 62

patients were treated. Bone tunnel width was measured by CT scans, while clinical efficacy was assessed by patient-administered outcome instruments (WOMAC, IKDC 2000) up to 1 year following the ACL reconstruction in patients receiving either ACS (Group A) or placebo (Group B). We compared the levels and dynamics of IL-1 β concentrations in the synovial liquid and examined the correlation between the levels of IL-1 β at three different postoperative points.

Results Bone tunnel enlargement was significantly less (6 months: 8%, 12 months: 13%) in Group A than in Group B (6 months: 31%, 12 months: 38%). Clinical outcomes (WOMAC, IKDC 2000) were consistently better in patients treated with ACS at all data points and for all outcome parameters, and there were statistically significant differences in the WOMAC stiffness subscale after 1 year. The decrease in IL-1 β synovial fluid concentration was more pronounced in the ACS group, and values were lower, to a statistically significant degree, in the ACS group at day 10.

Conclusion The intraarticular administration/injection of ACS results in decreased bone tunnel widening after ACL reconstructive surgery.

Level of evidence Therapeutic study, Level I (randomized controlled trial [significant differences and narrow confidence intervals]).

Keywords ACL reconstruction · Autologous conditioned serum · ACS · Osteoarthritis · Interleukin-1 receptor antagonist (IL-1Ra) · Growth factors

Introduction

According to available literature, anterior cruciate ligament (ACL) reconstruction can be unsuccessful in up to 25% of

N. Darabos (✉) · D. Bartolek
University Clinic for Traumatology, Medical School,
University of Zagreb, Draskoviceva 19, 10000 Zagreb, Croatia
e-mail: darabos.dr@vz.t-com.hr

D. Bartolek
e-mail: dubravka.bartolek1@zg.t-com.hr

M. Haspl
Special Hospital for Orthopaedics and Traumatology Akromion,
Ljudevita Gaja 2, 49 217 Krapinske Toplice,
Croatia
e-mail: miroslav.haspl@akromion.hr

C. Moser · D. Groenemeyer
Groenemeyer Institute for Microtherapy, University
Witten-Herdecke, Universitaetsstrasse 142,
44799 Bochum, Germany
e-mail: moser@microtherapy.de

D. Groenemeyer
e-mail: groenemeyer@microtherapy.de

A. Darabos
Scientific Unit, General Hospital Varazdin,
Mestrovicova 1, 42000 Varazdin, Croatia
e-mail: anela.darabos@vz.t-com.hr

cases, due to a variety of causes [31, 62]. Postoperative widening of the tibial and the femoral tunnel, visible on radiological images, is one of the causes that has been identified. The impact of tunnel widening is still unclear, since tunnel widening results in greater knee laxity, but contrariwise is frequently observed in patients that are doing well, objectively and subjectively.

Tunnel widening can potentially complicate an ACL revision procedure [43, 70, 77]. Revision surgery involves staged reconstruction and additional surgical procedures and entails significant costs. Wide tunnels also alter the direction of the graft within a joint. Not only does this require a second surgery, but the potential for additional giving-way episodes further risks injury to the menisci and articular cartilage.

Bone tunnel widening occurs over time, not immediately after surgery [9]. Several authors [9, 24, 55, 66] found that tunnel widening occurred early and stabilized within a year. Others have observed tunnel widening to progress up to 2 years after surgery [24, 38, 56, 57, 73, 74].

The exact etiology of tunnel widening is unknown. The most prominent factor that contributes to enlargement is the choice of graft. It is more commonly found when pure tendon grafts are used, compared with bone patellar tendon autografts [8, 13, 14, 19, 32, 35, 42, 57, 65, 74, 76, 81]. However, a few surgeons have also reported contrary results [14].

A number of biological and mechanical etiologies have been suggested as the cause of tunnel widening. The postulated mechanical factors include local stress deprivation of the tunnel wall (cell necrosis caused by drilling and graft remodeling) [6], the windshield-wiper effect and the bungee cord effect [19, 38], graft-tunnel motion [6], aggressive rehabilitation [7, 20, 67, 81], graft fixation [4, 12, 19, 25, 39, 41, 48–50, 59, 60], and increased graft forces due to improper graft placement [8, 27, 31–33, 38, 63].

There are many potential biological explanations. Graft swelling, the use of allograft tissue (a cytokine-mediated nonspecific inflammatory response), synovial fluid propagation within bony tunnels ("synovial bathing effect") [10, 14], and increased cytokine levels creating a hostile environment within the joint (as a result of toxic products including ethylene, oxide, and metal) are biological modes that could induce osteolysis and tunnel widening [15, 24, 33, 34, 36, 37, 52, 82].

After ligament injuries or ruptures, large increases in the pro-inflammatory cytokines occur acutely [15, 26, 82]. Elevated IL-1 β and TNF- α were detected, supporting the hypothesis that these cytokines were related to bone resorption induced by the biological activity of cytokines and depletion of growth factors, i.e., osteoclast activation and subsequent osteolysis. [16, 18, 29, 36, 40, 52, 68, 75]. Associated injuries such as bone bruises and meniscal tears

may affect the cytokine profile. Of the cytokines identified as playing a role, interleukin-1 (IL-1) appears to be of pivotal importance [15, 33, 36]. Although much remains to be discovered, it is known that IL-1 β inhibits the synthesis of the matrix and also promotes its degeneration, whereas certain cytokines and growth factors, especially insulin-like growth factor-1 (IGF-1), transforming growth factor- β (TGF- β), and several bone morphogenic proteins (BMPs), promote matrix and bone synthesis [16, 17, 29, 36, 40, 68, 69, 75]. Moreover, IL-1Ra apparently becomes depleted over time and tends to be undetectable in chronic ACL situations. Consequently, the cartilage-protective function of this cytokine is lost [82]. In animal models of arthritis and inflammation, as well as in clinical trials, blockage of IL-1 β by IL-1Ra can slow the progression of disease [2, 3, 11, 21, 22, 30, 45, 54, 80]. Thus, the inhibition of IL-1 β may be an important strategy for decreasing tissue degeneration and destruction [36, 45].

A new treatment alternative that draws on knowledge of the role played by cytokines and growth factors is autologous conditioned serum (ACS) that is produced from the patient's own blood [47, 75]. This novel, biologically based therapeutic agent was suggested from the observations of Meijer et al. [47], who found that exposure of blood to pyrogen-free surfaces selectively elicited a vigorous, rapid increase in the synthesis of anti-inflammatory cytokines, specifically IL-1Ra, fibroblastic growth factor-1 (FGF-1), hepatocyte growth factor (HGF), and transforming growth factor- β 1 (TGF- β 1), resulting in higher concentrations of those cytokines and factors in human blood serum. For the ACS production, venous blood is drawn into syringes containing pre-treated glass beads (Orthokine EOT Syringe, Orthogen, Duesseldorf, Germany). When the blood is incubated for 6–9 h, the increase in IL-1Ra is comparable to that observed in cultures of purified monocytes exposed to immobilized IgG. There is no noticeable induction of IL-1 β or TNF- α . Extensive cell death does not occur, hemolysis is mild and not clinically remarkable, and the major serum protein composition is not affected. After incubation, the blood is centrifuged and the serum is extracted. The resulting product, which is known as autologous conditioned cell-free serum (ACS), is then portioned and either stored until needed or injected into the affected region of the patient.

The specific aim of the present randomized controlled trial (RCT) was to use intraarticular ACS injections as a way to reduce the IL-1 β influence on the process of ACL healing. The study objectives were (1) to measure and compare the width of the tibial bone tunnel, at day 1, and 6 and 12 months after ACL reconstruction in patients treated with ACS or placebo injections (*Bone tunnel widening*); (2) to measure and compare the levels and dynamics of IL-1 β concentrations in the synovial fluid at three different

postoperative time points and to determine whether the IL-1 β -dependent catabolic effects will decrease after postoperative intraarticular injection of ACS with the accompanying increased levels of IL-1Ra (*IL-1 β effects*); (3) to demonstrate that patients' state of health has improved from baseline assessment and to evaluate differences in the two treatment groups concerning clinical outcome (*Effectiveness and patients' state of health*); (4) to assess the nature and duration of any serious and/or minor adverse events (AE) subsequent to ACS injections (*Treatment safety*).

Materials and methods

In a prospective, randomized, double-blinded, placebo-controlled trial with two parallel groups, 62 patients were treated. This trial was conducted over a period of 27 months; the first patient was enrolled in 2006, and the last patient completed follow-up in 2008. Each patient was fully informed about the purpose of the trial, expected benefits, possible risks, and all the other details pertaining to the study. All participants signed an informed consent. Approval for this study was obtained from the Ethical Board, School of Medicine, University of Zagreb, prior to performing the study.

Eligible patients were older than 18 years. Prior to each surgery, traumatic ACL rupture was determined on the basis of a clinical examination and confirmed by exploratory and therapeutic arthroscopic surgery in accordance with good surgical practice to confirm the ACL tear and address any meniscal or chondral injury. The present study included patients with the same preoperative diagnosis of isolated ACL rupture, a knee axis deviation up to 5° and knee chondral lesions up to grade 2 according to the Outerbridge classification.

Exclusion criteria were poor general health as judged by the orthopedic surgeon; concomitant painful or disabling disease of the spine, hips, or lower limbs that would interfere with the evaluation of the afflicted knee; any inflammatory and infectious arthropathies; alcohol/drug abuse and morbid obesity.

Surgical intervention

The data used in this study are from the study diaries, according to the patient's operative and postoperative protocols. The same surgeon operated (ND) on all patients during a period of 6 months after the injury. The subjects underwent surgical reconstruction of a traumatic ACL rupture using autograft of the semitendinosus and gracilis tendons (HS), as well as of the patellar ligament (BTB). An endoscopic technique was used in all cases. Numerous

anatomical, radiographic, cadaveric as well as clinical studies on the performed surgical procedures are available in literature. Thirty-two patients were randomized to receive BTB and 30 patients to receive HS reconstruction.

The drill diameter used for the tibial tunnel averaged 8.6 ± 0.7 mm (range 7–10 mm). At femoral site, 27 patients were fixed with the use of Bio Trans Fix (Arthrex, US) and 35 with Rigid Fix (Mytek, US). In all cases, at the tibial site, an interferent screw was used. In the present trial, procedures were equal in all patients.

Postoperative treatment protocol

Participants who met all inclusion and exclusion criteria were randomized to either the ACS or the saline group. A computer-generated randomization list was produced by a trial coordinator at the external blood-processing site, who allotted the participants either to the ACS or the saline group in a sequential manner according to the randomization code but was not otherwise involved in the trial. A 60 ml sample of whole blood was taken from each participant using the special syringe containing pre-treated glass beads. Processing including centrifugation, microfiltration (0.2 μ m, Millipore), and aliquoting into four 2-ml portions was performed in accordance with the manufacturers' recommendations. The ACS production as well as the reproducible elevation of biologic factors within the serum is described in detail in references [47, 75].


The aliquots were frozen at -20°C . Samples from patients who had been randomized to the saline group were discarded. Throughout the study, the participants and their observing (interviewing) doctors were blinded to the treatment to which the patients were assigned. All procedures were identical for both the ACS and the saline injections. Because the ACS and the saline solutions are different colors, blinding of the administering doctor was not possible. Therefore, the blind observer technique was chosen to obtain double-blind conditions.

Subsequently, an injection regime of 4 injections was started in a rigid schedule comprising 11 days: injections were given on day 0 (day of surgery), day 1, day 6, and day 10. The synovial fluids present were aspirated to minimize drug dilution and for ELISA testing. The needles were left in place and either 2 ml of ACS or 2 ml of physiological saline was injected through a 0.20-mm-pore-size antibacterial sterile filter.

Demographic and baseline disease characteristics

A total of 112 patients were screened for possible inclusion in the study. Fifty were excluded because they did not meet the inclusion/exclusion criteria or withdrew voluntarily after receiving written and oral information (Fig. 1).

Fig. 1 The consort flowchart



Sixty-two patients met the inclusion criteria and did not have exclusion criteria and were randomized to receive ACS ($n = 31$) or placebo ($n = 31$). No patient was completely lost to follow-up. During the course of the study, we were not able to collect complete data sets from 6 patients from the ACS group and 9 patients from placebo group at different time points (Fig. 1). The data sets for the participants were completed using the "last observation carried forward" (LOCF) method.

Baseline values of both treatment groups were comparable. No significant differences between the treatment groups were found with respect to age ($P = 0.12$), gender, weight, or body mass index (BMI) before and during the study period (Table 1).

CT scans: bone tunnel widening

Tunnel widening was determined using standardized CT scans [46]. The CT was chosen for evaluating the tunnel

Table 1 Baseline demographics and disease characteristics

	ACS	Placebo	<i>P</i> value
<i>N</i>	31	31	
Age	30.6 ± 9.8	35.2 ± 12.4	n.s.
BMI	25.7 ± 2.8	26.5 ± 3.7	n.s.
Gender (% male/female)	68/32	87/13	n.s.
Activity level (IKDC)	2.32 ± 0.7	2.48 ± 0.8	n.s.
WOMAC pain	2.68 ± 1.6	3.31 ± 2.0	n.s.
WOMAC stiffness	3.24 ± 2.0	3.65 ± 1.3	n.s.
WOMAC function	2.65 ± 1.5	2.9 ± 1.6	n.s.
GLOBAL WOMAC	2.71 ± 1.4	3.05 ± 1.5	n.s.
IKDC 2000	27.1 ± 13.7	27.7 ± 13.3	n.s.

Values are Mean ± SD

diameter because it gives a true measurement, especially in the tunnel of patients who undergo BTB autografts [23, 32, 73]. The measurements of tibial tunnel width at a level of 1 cm below articular surface were taken on postoperative

day 1, and 6 and 12 months after operative treatment by means of CT scans and assessment of the scans by two independent experts (intra- and inter-observer blinded).

Intraarticular IL-1 concentration

The intraarticular concentration of IL-1 β was measured on postoperative day 1, day 6, and day 10. Measurements of IL-1 β in serum and synovial fluid were performed by an independent expert using a Human IL-1 β /IL-1F2 Quantikine ELISA Kit (Minneapolis, MN, USA).

Effectiveness, safety, and patients' state of health

To evaluate the clinical efficacy and the possible correlation between the tunnel widening at follow-up and the clinical outcome, well-known patient-administered outcome instruments were used (Western Ontario and McMaster Universities Osteoarthritis Index [WOMAC]) and International Knee Documentation Committee Score [IKDC 2000]). At 6 and 12 months after surgery, the patients completed the same questionnaires as at baseline. At these follow-up visits, the treating orthopedic surgeon performed a physical examination of the knee, completed the surgeon part of the IKDC 2000, and checked for adverse events and changes in analgesic use.

Statistical analysis

Statistical analysis was done using SPSS for Windows on a personal computer. At baseline, homogeneity of demographic and disease characteristics was tested with an ANOVA one-way method for continued parameter and a Chi-square test for categorical parameter. A general linear model for repeated measurement was used to compare the longitudinal profile of the groups and a multiple comparison between the groups was performed. The changes from

baseline and comparisons of groups for all scores were calculated using an ANOVA one-way test. Although randomization was stratified for graft types, sub-analysis was performed for these groups. Patients who were considered treatment failures were excluded from further follow-up. The data sets for the participants considered treatment failures were completed using the "last observation carried forward" method.

Results are presented graphically, using the mean profile per group and analytically reporting the *P* values for each contrast. *P* values less than 0.05 were considered statistically significant.

Results

CT scans: bone tunnel widening

Sixty-one of sixty-two tunnels had enlarged compared with the diameter of the drill in the 12 month post-op, regardless of trial medication, type of fixation, and irrespective of graft type. Statistically significant differences were found in the enlargement between surgery and 6 and 12-month post-op (Fig. 2a–c, Table 2).

Irrespective of treatment modality (ACS or placebo), tunnel widening was marked in the HS group. In the HS group, the mean increase in the tibial tunnel area was 33.2% (range 6–105%) after 6 months and 41.7% (range 8–108%) after 12 months. In the BTB group, it was only 11.1% (range –2–48%) after 6 months and 17.1% (range 3–69%) after 12 months.

The effect of ACS and placebo treatment over time on the bone tunnel widening is presented in Fig. 3. With respect to the treatment groups (ACS vs. placebo), the magnitude of tunnel enlargement was statistically significant higher in patient knees treated with placebo/saline at 12 months in the BTB group and at 6 and 12 months in the




Fig. 2 Computed tomography evaluation of bone tunnel widening. Example of TW results a Day 1 postoperatively, b 6 months postoperatively, c 12 months postoperatively

Table 2 CT measurement of tibial bone tunnel enlargement in millimetres (mm)

	ACS	Placebo	P value
<i>Bone-Tendon-Bone (BTB) N = 32</i>			
Day 0	10.1 ± 0.3	10.0 ± 0.04	0.362
6 months	10.8 ± 0.6	11.4 ± 1.1	0.061
12 months	11.2 ± 0.6	12.6 ± 1.5	0.001*
<i>Hamstring (HS) N = 30</i>			
Day 0	7.9 ± 0.6	7.86 ± 0.70	0.098
6 months	9.3 ± 1.1	10.95 ± 1.84	0.032*
12 months	9.5 ± 0.8	11.34 ± 1.94	0.048*

Absolute values and comparison by treatment group (ACS vs. placebo)

* Significant difference $P < 0.05$ between ACS and Placebo




Fig. 3 Bone tunnel widening as a function of time, graft type, and treatment form. Figure showing mean + SEM. *Significant difference $P < 0.05$ between ACS and Placebo. The effect of ACS and placebo treatment over time on bone tunnel widening

HS group (each $P < 0.05$) (Table 2). Note that the tunnel widening in the ACS group is only half that in the placebo group after 6 and 12 months.

Intraarticular IL-1 concentration

In the overall study population, synovial fluid (SF) concentrations postoperatively at day 1 were significantly higher than normal values (Fig. 4). Subsequently, the IL-1 β SF concentration dropped off significantly in both groups and reached approximately normal values by day 6 (in both groups each P at day 6 was below 0.05 for the comparison with day 1 values). Beyond day 6, the ACS and placebo groups reacted differently. In the ACS group, the values continued to decline until day 10 (ACS day 10: mean 3.4 pg/l), whereas in the placebo group the IL-1 β concentrations again tended to increase till day 10 (placebo day 10: mean 16.0 pg/l). The difference at day 10 was




Fig. 4 IL-1 β synovial fluid concentrations over time as a function of treatment group. Figure showing mean + SEM. *Significant difference $P < 0.05$ between ACS and Placebo

statistically significant ($P = 0.038$ for the comparison ACS vs. placebo). The IL-1 β concentrations found in the ACS group at day 10 were a little lower than normal values given in the literature.

However, nearly all patients had higher postoperative IL-1 β synovial fluid concentrations (except ACS day 10), and there was no significant correlation between bone tunnel widening and postoperative IL-1 β concentration ($P > 0.05$). Subsequent stratification of the results revealed no correlation between IL-1 β SF concentrations and graft type used (HS vs. BTB).

Patients' assessment of treatment efficacy

Both ACS-treated and placebo-treated patients showed a significant improvement on all outcome measures ($P < 0.001$) according to WOMAC and IKDC 2000, compared with baseline values. ACS-treated patients scored consistently better with the lowest pain scores and the largest reduction (Table 3) than did the placebo-treated patients.

As far as improvement over time is concerned, ACS resulted in significantly more improvement in WOMAC stiffness scores ($P = 0.047$, 12 months) compared with placebo treatment. Comparable improvements were found for ACS and placebo treatments in terms of the WOMAC global index (71% vs. 61% at 6 months, and 89% vs 79% after 12 months; n.s.).

Clinical examination

Baseline disease characteristics were comparable in the two groups according to the IKDC 2000 clinical examination and surgeon's part. When the participants were stratified by groups after 6 months, there were significantly lower effusion values (assessed by ballotting the knee) in the ACS group. In the ACS group, 70% had no effusion and 30% had mild effusion, whereas in the placebo group only 35% had no effusion and 64% had mild effusion.

Table 3 Clinical outcome parameters (WOMAC, IKDC 2000 [subjective knee evaluation])

	WOMAC global	WOMAC pain	WOMAC stiffness	WOMAC function	IKDC 2000 SKE
ACS					
Baseline	2.7 ± 1.4	2.7 ± 1.6	3.2 ± 2.0	2.7 ± 1.5	27.1 ± 13.7
6 months	0.8 ± 0.9	0.9 ± 1.0	1.0 ± 1.1	0.7 ± 0.9	61.8 ± 13.3
12 months	0.3 ± 0.5	0.4 ± 0.7	0.3* ± 1.4	0.3 ± 0.5	75.5 ± 17.5
Placebo					
Baseline	3.1 ± 1.5	3.3 ± 2.0	3.7 ± 1.3	2.9 ± 1.6	27.7 ± 13.3
6 months	1.2 ± 1.4	1.3 ± 1.5	1.4 ± 1.5	1.1 ± 1.3	56.1 ± 16.6
12 months	0.6 ± 1.0	0.5 ± 0.9	0.9 ± 1.4	0.6 ± 1.1	71.5 ± 18.1

Values are given for the complete data set (all patients)

Values are mean ± SD. For the WOMAC, a lower score represents a better outcome; the possible values range from 0 (best score) to 10 (worst score). In contrast, for the IKDC 2000, 0 indicates most severe disability and 100 no pain or disability

* Indicates statistically significant difference between groups; $P < 0.05$ for the comparison with placebo

Significantly more patients in the ACS group had better results on functional tests, achieving a ratio of >90% of one-leg hops with their index knee, compared with their normal knee. Other measurements were very similar (e.g., no difference in laxity, about 60% in ACS group vs. 65% in the placebo group were rated as tight).

Overall, after 12 months, there was a further improvement in both groups, but with diminished differences between groups. There was no longer any significant difference in effusion (e.g., 80% of patients with no effusion in ACS group vs. 76% in the placebo group) or in functional one-leg hops, and still no difference in laxity. About 62% of ACS patients and 69% of placebo patients were rated as tight.

The range of motion (ROM) was significantly better in the ACS group. About 97% of patients in this group had full range of motion. In the placebo group, 2 patients had a lack of extension (3–5°) and 4 had a lack of flexion (6–15°), whereas only 1 patient from the ACS group had a lack of flexion (6–15°). Additionally, we found less harvest site pathologies (tenderness, irritation, or numbness at the autograft harvest site) in the ACS group. Seventy-six percentage had no such problems, 21% had mild problems, and only 3.4 had moderate problems. In contrast, in the placebo group, only 58% had no problems at the harvest site, 23% had mild, and 19% had moderate problems.

Subsequent stratification of the patient-administered outcome parameters as well as the clinical examination result revealed no correlation between tunnel widening and clinical outcome. Interestingly, sub-analysis for graft type did not show statistically significant differences in clinical outcomes between the subgroups, as measured by WOMAC or IKDC. In addition, correlation analysis did not show significant relations between baseline patient characteristics (age, gender, and symptom severity) and treatment outcome.

Safety: adverse events

In general, all intraarticular injections were well tolerated: adverse events were only mild to moderate and most consisted of a subjective pain or pressure sensation directly after the IA injections and revealed within a few hours without secondary damage. There was no statistically significant difference in the prevalence of adverse events between the two groups as a very good risk/benefit ratio and excellent safety record has already been demonstrated for ACS in other clinical trials. There were no infections or severe adverse events related to the study procedure or medication in this trial.

Discussion

The most important finding of the present randomized controlled trial was that a standardized postoperative treatment regimen with intraarticular administration of ACS was able to influence outcome parameters different from placebo treatment. The statistically significant reduction in bone tunnel enlargement and the statistically significant improvement of WOMAC stiffness together with the consistently higher, though nonstatistically significant, improvement of clinical parameters demonstrate that ACS induces a biological response and warrant future investigations into the possible effects of ACS.

The cause of bone tunnel widening is unclear, but it is thought to be multifactorial, with mechanical and biological factors playing a role [61, 62]. Although this present study cannot prove it alone, there are findings that favor biological factors play a more important role in tunnel enlargement than mechanical ones. In the present trial, it was shown that there is an association between tibial bone tunnel enlargement and elevated synovial fluid

concentrations of IL-1 β concentrations postoperatively after ACL reconstruction, indicating a potential involvement of these biological mediators in the pathogenesis of bone tunnel widening [15]. However, there was no difference in the contents of synovial fluid between HS and BTB ACL, suggesting that the biological response in both of these types of autografts is similar. The present study as well as previously published trials show that the type of the fixation appears not to have a determinant effect on tunnel enlargement, since enlargement occurs irrespective of fixation type, suggesting that the enlargement may be more of a biological than a mechanical phenomenon. There was also variation in bone tunnel widening between patients, even among patients treated with similar grafts, fixation devices and methods, same surgeon, and rehabilitation protocol. These findings cannot be explained by biomechanical factors only. As in previously published studies, no significant correlations were found between the aforementioned outcome measures and the tunnel widening at 12-month follow-up in our patients, but bone tunnel enlargement after ACL reconstruction has been suggested to play an important role for revision ACL surgery, which is necessary in about 8% of patients after ACL reconstruction [77].

Advances in molecular and cellular biology are beginning to influence the clinical practice of orthopaedics. Novel, biologically based therapeutic agents like ACS promise to improve the management of a variety of orthopedic conditions through the inhibition of catabolic cytokines and the local administration of autologous anabolic growth factors [44, 51, 53, 72]. Autologous conditioned serum (ACS) is produced from the patient's own blood and can be manufactured with ease at the point of care. When results like from the present trial need to be explained, we have to turn to the previous works on this new treatment strategy. ACS has been used in more than 30,000 humans and 10,000 horses. It has recently been shown to be effective in two randomized controlled osteoarthritis trials [3, 80] and in an RCT on the treatment of sciatic back pain [5]. It has been proved to improve clinical lameness in horses significantly [28], and to enhance healing of muscle and tendon injuries in animals [44, 79] as well as in human athletes [78].

There are many products and devices on the market derived from blood; however, this product is different from platelet-rich plasma (PRP) or autologous conditioned plasma (ACP) preparations, because besides the simple concentration of blood own factors, it leads through incubation in a special created surrounding to the production of IL-1Ra (partly de novo) in order to decrease the inflammation cytokine. Because of the autologous nature of the treatment (meaning that only substances originating from the patient's own body are used) and the physiological

levels of cytokines and growth factors that are achieved, the risk/benefit ratio is excellent.

There is an urgent need for consensus about postoperative treatment strategies to enhance the speed and safety in which a patient regains the pre-injury level of function or an athlete returns to sport. Preclinical patient education, an optimal timing of surgery, exact starting times of postoperative regimens, and control of the rehabilitation aims with reliable tests could enable a less-complicated rehabilitation course [1, 58, 64, 71]. In the present trial, absolute values of the WOMAC and IKDC outcome measures showed that ACS-treated patients scored consistently better, compared with placebo-treated patients. In addition, ACS treatment was found to result in statistically significant more improvement on the WOMAC stiffness score after 6 months. However, the differences disappeared over time, but when looking at the different results you can see that treating with ACS could reach earlier better functional outcomes and may be the subtle distinction that could cause the difference of success or failure after surgery. However, additional studies are necessary to determine which strategies could optimize outcome most efficiently and to better estimate the expected benefits of the treated patients.

One possible limitation of this study is that the CT scans were performed 12 months after surgery and the enlargement could not be finished yet. Revision surgery causes significant extra costs, but since the trial has a relatively short follow-up period, it is currently not possible to proof if this postoperative ACS treatment protocol has an influence on that or if there might be a decreased concern in revision surgeries about tunnel enlargement in ACS-treated patients. The main concern surgeons have about TW is the possibility of subsequent ligament laxity. Yet in the present study, as in other studies, ligament laxity did not occur. No significant differences in stability (elongation or rupture of the graft) comparing HS and BTB were found. However, besides standardized clinical examination by a specially trained surgeon, no objective measurement of knee stability was done in this trial.

One major point in this trial was that the surgery itself helped most in patients suffering from ACL deficiency independent of postsurgical treatment. Ultimately, the trial objective was mainly to determine effects of ACS as a new treatment, compared with placebo, and not focus on the differences between the surgical options. Different fixation methods could also lead to other clinical and functional outcomes, but there remains considerable debate regarding the actual optimal choice, making clinical application challenging. Yet, in the present trial, all surgical procedures of tibial fixation were performed by the same surgeon, and interferent screws lengths, materials, and application techniques were the same in all cases.

566 Conclusion

567 Novel technologies and standardized postoperative treat-
568 ment regimens such as those described in the present RCT
569 may provide useful therapeutic procedures to enhance
570 biological healing after reconstructive surgery.

571 Autologous conditioned serum (ACS) appears to have a
572 beneficial biological effect on patient-documented symp-
573 toms and structure modifying effects arising after ACL
574 reconstructive surgery, although this hypothesis remains to
575 be studied in future clinical trials.

576 **Acknowledgments** The trial was an investigator-initiated, pro-
577 spective, double-blind, reference-controlled study. The source of all
578 funding for the study has been obtained by the National Health
579 Insurance. We thank Vera Srsan Zivanovic (Department of General
580 Surgery and Traumatology, General Hospital Varazdin), Renata Jug
581 (Institute of Immunology, Zagreb), Damir Poljak (Department of
582 Transfusiology, General Hospital Varazdin), and Darko Kranjcec
583 (Department of General Surgery and Traumatology, General Hospital
584 Varazdin).

585 **Conflict of interest** The authors declare that they have no conflict
586 of interest.
587

588 References

- 589 1. Andersson D, Samuelsson K, Karlsson J (2009) Treatment of
590 anterior cruciate ligament injuries with special reference to sur-
591 gical technique and rehabilitation: an assessment of randomized
592 controlled trials. *Arthroscopy* 25:653–685
- 593 2. Arend WP (1993) Interleukin-1 receptor antagonist. *Adv Immu-
594 nol* 54:167–227
- 595 3. Baltzer AW, Moser C, Jansen SA et al (2009) Autologous con-
596 ditioned serum (Orthokine) is an effective treatment for knee
597 osteoarthritis. *Osteoarthritis Cartil* 17:152–160
- 598 4. Baumfeld JA, Diduch DR, Rubino LJ et al (2008) Tunnel wid-
599 ening following anterior cruciate ligament reconstruction using
600 hamstring autograft: a comparison between double cross-pin and
601 suspensory graft fixation. *Knee Surg Sports Traumatol Arthrosc*
602 16:1108–1113
- 603 5. Becker C, Heidersdorf S, Drewlo S et al (2007) Efficacy of
604 epidural perineural injections with autologous conditioned serum
605 for lumbar radicular compression: an investigator-initiated, pro-
606 spective, double-blind, reference-controlled study. *Spine*
607 32:1803–1808
- 608 6. Berg EE, Pollard MB, Kang Q (2001) Interarticular bone tunnel
609 healing. *Arthroscopy* 17:189–195
- 610 7. Bohnsack M, Hehl S, Moller H et al (2006) Influence of the
611 postoperative activity level on tibial bone tunnel enlargement and
612 functional treatment results following anterior cruciate ligament
613 reconstruction using a patellar tendon autograft. *Z Orthop Ihre
614 Grenzgeb* 144:373–379
- 615 8. Brown CH Jr, Wilson DR, Hecker AT et al (2004) Graft-bone
616 motion and tensile properties of hamstring and patellar tendon
617 anterior cruciate ligament femoral graft fixation under cyclic
618 loading. *Arthroscopy* 20:922–935
- 619 9. Buck DC, Simonian PT, Larson RV et al (2004) Timeline of
620 tibial tunnel expansion after single-incision hamstring anterior
621 cruciate ligament reconstruction. *Arthroscopy* 20:34–36
- 622 10. Buelow JU, Siebold R, Ellermann A (2002) A prospective eval-
623 uation of tunnel enlargement in anterior cruciate ligament
624 reconstruction with hamstrings: extracortical versus anatomical
625 fixation. *Knee Surg Sports Traumatol Arthrosc* 10:80–85
- 626 11. Chevalier X, Giraudeau B, Conrozier T et al (2005) Safety study
627 of intraarticular injection of interleukin 1 receptor antagonist in
628 patients with painful knee osteoarthritis: a multicenter study.
629 *J Rheumatol* 32:1317–1323
- 630 12. Choi NH, Lee JH, Son KM et al (2010) Tibial tunnel widening
631 after anterior cruciate ligament reconstructions with hamstring
632 tendons using Rigidfix femoral fixation and Intrafix tibial fixa-
633 tion. *Knee Surg Sports Traumatol Arthrosc* 18:92–97
- 634 13. Clark JC, Rueff DE, Indelicato PA et al (2009) Primary ACL
635 reconstruction using allograft tissue. *Clin Sports Med* 28:223–244
636 (viii)
- 637 14. Clatworthy MG, Annear P, Bulow JU et al (1999) Tunnel wid-
638 ening in anterior cruciate ligament reconstruction: a prospective
639 evaluation of hamstring and patella tendon grafts. *Knee Surg
640 Sports Traumatol Arthrosc* 7:138–145
- 641 15. Darabos N, Hundric-Haspl Z, Haspl M et al (2009) Correlation
642 between synovial fluid and serum IL-1beta levels after ACL
643 surgery-preliminary report. *Int Orthop* 33:413–418
- 644 16. Dinarello CM (1999) Proinflammatory and anti-inflammatory
645 cytokines. *Rheumatoid Arthritis*
- 646 17. Evans CH, Ghivizzani SC, Robbins PD (2009) Orthopedic gene
647 therapy in 2008. *Mol Ther* 17:231–244
- 648 18. Evans CH, Gouze JN, Gouze E et al (2004) Osteoarthritis gene
649 therapy. *Gene Ther* 11:379–389
- 650 19. Fauno P, Kaalund S (2005) Tunnel widening after hamstring
651 anterior cruciate ligament reconstruction is influenced by the type
652 of graft fixation used: a prospective randomized study. *Arthrosc-
653 opy* 21:1337–1341
- 654 20. Feller JA, Webster KE, Taylor NF et al (2004) Effect of phys-
655 iotherapy attendance on outcome after anterior cruciate ligament
656 reconstruction: a pilot study. *Br J Sports Med* 38:74–77
- 657 21. Fernandes J, Tardif G, Martel-Pelletier J et al (1999) In vivo
658 transfer of interleukin-1 receptor antagonist gene in osteoarthritic
659 rabbit knee joints: prevention of osteoarthritis progression. *Am J
660 Pathol* 154:1159–1169
- 661 22. Fernandes JC, Martel-Pelletier J, Pelletier JP (2002) The role of
662 cytokines in osteoarthritis pathophysiology. *Biorheology*
663 39:237–246
- 664 23. Figueroa D, Melean P, Calvo R et al (2010) Magnetic resonance
665 imaging evaluation of the integration and maturation of semi-
666 tendinosus-gracilis graft in anterior cruciate ligament recon-
667 struction using autologous platelet concentrate. *Arthroscopy*
668 26:1318–1325
- 669 24. Fink C, Zapp M, Benedetto KP et al (2001) Tibial tunnel
670 enlargement following anterior cruciate ligament reconstruction
671 with patellar tendon autograft. *Arthroscopy* 17:138–143
- 672 25. Foldager C, Jakobsen BW, Lund B et al (2010) Tibial tunnel
673 widening after bioresorbable poly-lactide calcium carbonate
674 interference screw usage in ACL reconstruction. *Knee Surg
675 Sports Traumatol Arthrosc* 18:79–84
- 676 26. Frank C, Amiel D, Woo SL et al (1985) Normal ligament prop-
677 erties and ligament healing. *Clin Orthop Relat Res* 196:15–25
- 678 27. Frank RM, Seroyer ST, Lewis PB et al (2010) MRI analysis of
679 tibial position of the anterior cruciate ligament. *Knee Surg Sports
680 Traumatol Arthrosc* 18:1607–1611
- 681 28. Frisbie DD, Kawcak CE, Werpny NM et al (2007) Clinical, bio-
682 chemical, and histologic effects of intra-articular administration
683 of autologous conditioned serum in horses with experimentally
684 induced osteoarthritis. *Am J Vet Res* 68:290–296
- 685 29. Goldring SR, Goldring MB (2004) The role of cytokines in
686 cartilage matrix degeneration in osteoarthritis. *Clin Orthop Relat
687 Res* 427:S27–S36

30. Granowitz EV, Clark BD, Mancilla J et al (1991) Interleukin-1 receptor antagonist competitively inhibits the binding of interleukin-1 to the type II interleukin-1 receptor. *J Biol Chem* 266:14147–14150
31. Herbert M, Lenschow S, Fu FH et al (2010) ACL mismatch reconstructions: influence of different tunnel placement strategies in single-bundle ACL reconstructions on the knee kinematics. *Knee Surg Sports Traumatol Arthrosc* 18:1551–1558
32. Hersekli MA, Akpınar S, Ozalay M et al (2004) Tunnel enlargement after arthroscopic anterior cruciate ligament reconstruction: comparison of bone-patellar tendon-bone and hamstring autografts. *Adv Ther* 21:123–131
33. Hoher J, Möller HD, Fu FH (1998) Bone tunnel enlargement after anterior cruciate ligament reconstruction: fact or fiction? *Knee Surg Sports Traumatol Arthrosc* 6:231–240
34. Hollis R, West H, Greis P et al (2009) Autologous bone effects on femoral tunnel widening in hamstring anterior cruciate ligament reconstruction. *J Knee Surg* 22:114–119
35. Iorio R, Vadala A, Argento G et al (2007) Bone tunnel enlargement after ACL reconstruction using autologous hamstring tendons: a CT study. *Int Orthop* 31:49–55
36. Irie K, Uchiyama E, Iwasa H (2003) Intraarticular inflammatory cytokines in acute anterior cruciate ligament injured knee. *Knee* 10:93–96
37. Jacobs JJ, Roebuck KA, Archibeck M et al (2001) Osteolysis: basic science. *Clin Orthop Relat Res* 393:71–77
38. Jagodzinski M, Foerstemann T, Mall G et al (2005) Analysis of forces of ACL reconstructions at the tunnel entrance: is tunnel enlargement a biomechanical problem? *J Biomech* 38:23–31
39. Jagodzinski M, Geiges B, von Falck C et al (2010) Biodegradable screw versus a press-fit bone plug fixation for hamstring anterior cruciate ligament reconstruction: a prospective randomized study. *Am J Sports Med* 38:501–508
40. Kohno T, Ishibashi Y, Tsuda E et al (2007) Immunohistochemical demonstration of growth factors at the tendon-bone interface in anterior cruciate ligament reconstruction using a rabbit model. *J Orthop Sci* 12:67–73
41. Kuskucu SM (2008) Comparison of short-term results of bone tunnel enlargement between EndoButton CL and cross-pin fixation systems after chronic anterior cruciate ligament reconstruction with autologous quadrupled hamstring tendons. *J Int Med Res* 36:23–30
42. L'Insalata JC, Klatt B, Fu FH et al (1997) Tunnel expansion following anterior cruciate ligament reconstruction: a comparison of hamstring and patellar tendon autografts. *Knee Surg Sports Traumatol Arthrosc* 5:234–238
43. Maak TG, Voos JE, Wickiewicz TL et al (2010) Tunnel widening in revision anterior cruciate ligament reconstruction. *J Am Acad Orthop Surg* 18:695–706
44. Majewski M (2009) Accelerated healing of the rat Achilles tendon in response to autologous conditioned serum. *Am J Sports Med* 37:2117–2125
45. Manolagas SC, Jilka RL (1995) Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. *N Engl J Med* 332:305–311
46. Marchant MH Jr, Willimon SC, Vinson E et al (2010) Comparison of plain radiography, computed tomography, and magnetic resonance imaging in the evaluation of bone tunnel widening after anterior cruciate ligament reconstruction. *Knee Surg Sports Traumatol Arthrosc* 18:1059–1064
47. Meijer H, Reinecke J, Becker C et al (2003) The production of anti-inflammatory cytokines in whole blood by physico-chemical induction. *Inflamm Res* 52:404–407
48. Moislala AS, Jarvela T, Paakkala A et al (2008) Comparison of the bioabsorbable and metal screw fixation after ACL reconstruction with a hamstring autograft in MRI and clinical outcome: a prospective randomized study. *Knee Surg Sports Traumatol Arthrosc* 16:1080–1086
49. Myers P, Logan M, Stokes A et al (2008) Bioabsorbable versus titanium interference screws with hamstring autograft in anterior cruciate ligament reconstruction: a prospective randomized trial with 2-year follow-up. *Arthroscopy* 24:817–823
50. Nebelung W, Becker R, Merkel M et al (1998) Bone tunnel enlargement after anterior cruciate ligament reconstruction with semitendinosus tendon using Endobutton fixation on the femoral side. *Arthroscopy* 14:810–815
51. Nin JR, Gasque GM, Azcarate AV et al (2009) Has platelet-rich plasma any role in anterior cruciate ligament allograft healing? *Arthroscopy* 25:1206–1213
52. Nordstrom DC, Santavirta S, Aho A et al (1999) Immune responses to osteoarticular allografts of the knee—cytokine studies. *Arch Orthop Trauma Surg* 119:195–198
53. Orrego M, Larrain C, Rosales J et al (2008) Effects of platelet concentrate and a bone plug on the healing of hamstring tendons in a bone tunnel. *Arthroscopy* 24:1373–1380
54. Pelletier JP, Caron JP, Evans C et al (1997) In vivo suppression of early experimental osteoarthritis by interleukin-1 receptor antagonist using gene therapy. *Arthritis Rheum* 40:1012–1019
55. Peyrache MD, Djian P, Christel P et al (1996) Tibial tunnel enlargement after anterior cruciate ligament reconstruction by autogenous bone-patellar tendon-bone graft. *Knee Surg Sports Traumatol Arthrosc* 4:2–8
56. Pinczewski LA, Deehan DJ, Salmon LJ et al (2002) A five-year comparison of patellar tendon versus four-strand hamstring tendon autograft for arthroscopic reconstruction of the anterior cruciate ligament. *Am J Sports Med* 30:523–536
57. Pinczewski LA, Lyman J, Salmon LJ et al (2007) A 10-year comparison of anterior cruciate ligament reconstructions with hamstring tendon and patellar tendon autograft: a controlled, prospective trial. *Am J Sports Med* 35:564–574
58. Samuelsson K, Andersson D, Karlsson J (2009) Treatment of anterior cruciate ligament injuries with special reference to graft type and surgical technique: an assessment of randomized controlled trials. *Arthroscopy* 25:1139–1174
59. Sastre S, Popescu D, Nunez M et al (2010) Double-bundle versus single-bundle ACL reconstruction using the horizontal femoral position: a prospective, randomized study. *Knee Surg Sports Traumatol Arthrosc* 18:32–36
60. Schultz WR, McKissick RC, DeLee JC (2007) Tibial tunnel widening after hamstring tendon anterior cruciate ligament reconstruction: the effect of supplemental aperture fixation with autogenous bone cores. *Am J Sports Med* 35:1725–1730
61. Siebold R, Cafaltzis K (2010) Differentiation between intraoperative and postoperative bone tunnel widening and communication in double-bundle anterior cruciate ligament reconstruction: a prospective study. *Arthroscopy* 26:1066–1073
62. Silva A, Sampaio R, Pinto E (2010) Femoral tunnel enlargement after anatomic ACL reconstruction: a biological problem? *Knee Surg Sports Traumatol Arthrosc* 18:1189–1194
63. Silva A, Sampaio R, Pinto E (2010) Placement of femoral tunnel between the AM and PL bundles using a transtibial technique in single-bundle ACL reconstruction. *Knee Surg Sports Traumatol Arthrosc* 18:1245–1251
64. Strehl A, Egli S (2007) The value of conservative treatment in ruptures of the anterior cruciate ligament (ACL). *J Trauma* 62:1159–1162
65. Streich NA, Friedrich K, Gotterbarm T et al (2008) Reconstruction of the ACL with a semitendinosus tendon graft: a prospective randomized single blinded comparison of double-bundle versus single-bundle technique in male athletes. *Knee Surg Sports Traumatol Arthrosc* 16:232–238



- 820 66. Ugutmen E, Ozkan K, Guven M et al (2007) Early tunnel
821 enlargement after arthroscopic ACL reconstructions. *Acta Orthop*
822 Belg 73:625–629 852
- 823 67. Vadala A, Iorio R, De Carli A et al (2007) The effect of accel-
824 erated, brace free, rehabilitation on bone tunnel enlargement after
825 ACL reconstruction using hamstring tendons: a CT study. *Knee*
826 *Surg Sports Traumatol Arthrosc* 15:365–371 853
- 827 68. van't Hof RJ, Ralston SH (2001) Nitric oxide and bone. *Immu-*
828 *nology* 103:255–261 854
- 829 69. van den Berg WB (1999) The role of cytokines and growth
830 factors in cartilage destruction in osteoarthritis and rheumatoid
831 arthritis. *Z Rheumatol* 58:136–141 855
- 832 70. van Eck CF, Schreiber VM, Liu TT et al (2010) The anatomic
833 approach to primary, revision and augmentation anterior cruciate
834 ligament reconstruction. *Knee Surg Sports Traumatol Arthrosc*
835 18:1154–1163 856
- 836 71. van Grinsven S, van Cingel RE, Holla CJ et al (2010) Evidence-
837 based rehabilitation following anterior cruciate ligament recon-
838 struction. *Knee Surg Sports Traumatol Arthrosc* 18:1128–1144 857
- 839 72. Vogrin M, Rupprecht M, Dinevski D et al (2010) Effects of a
840 platelet gel on early graft revascularization after anterior cruciate
841 ligament reconstruction: a prospective, randomized, double-
842 blind, clinical trial. *Eur Surg Res* 45:77–85 858
- 843 73. Webster KE, Feller JA, Elliott J et al (2004) A comparison of
844 bone tunnel measurements made using computed tomography
845 and digital plain radiography after anterior cruciate ligament
846 reconstruction. *Arthroscopy* 20:946–950 859
- 847 74. Webster KE, Feller JA, Hameister KA (2001) Bone tunnel
848 enlargement following anterior cruciate ligament reconstruction:
849 a randomised comparison of hamstring and patellar tendon grafts
850 with 2-year follow-up. *Knee Surg Sports Traumatol Arthrosc*
851 9:86–91 860
- 852 75. Wehling P, Moser C, Frisbie DD et al (2007) Autologous
853 Conditioned Serum in the treatment of Orthopaedic diseases—
854 The Orthokine Therapy. *Biodrugs* 21:223–232 861
- 855 76. Wilson TC, Kantaras A, Atay A et al (2004) Tunnel enlargement
856 after anterior cruciate ligament surgery. *Am J Sports Med*
857 32:543–549 862
- 858 77. Wolf RS, Lemak LJ (2002) Revision anterior cruciate ligament
859 reconstruction surgery. *J South Orthop Assoc* 11:25–32 863
- 860 78. Wright-Carpenter T, Klein P, Schaferhoff P et al (2004) Treat-
861 ment of muscle injuries by local administration of autologous
862 conditioned serum: a pilot study on sportsmen with muscle
863 strains. *Int J Sports Med* 25:588–593 864
- 864 79. Wright-Carpenter T, Opolon P, Appell HJ et al (2004) Treatment
865 of muscle injuries by local administration of autologous condi-
866 tioned serum: animal experiments using a muscle contusion
867 model. *Int J Sports Med* 25:582–587 868
- 868 80. Yang KG, Raijmakers NJ, van Arkel ER et al (2008) Autologous
869 interleukin-1 receptor antagonist improves function and symp-
870 toms in osteoarthritis when compared to placebo in a prospective
871 randomized controlled trial. *Osteoarthr Cartil* 16:498–505 872
- 872 81. Yu JK, Paessler HH (2005) Relationship between tunnel widen-
873 ing and different rehabilitation procedures after anterior cruciate
874 ligament reconstruction with quadrupled hamstring tendons. *Chin*
875 *Med J (Engl)* 118:320–326 876
- 876 82. Zysk SP, Fraunberger P, Veihelmann A et al (2004) Tunnel
877 enlargement and changes in synovial fluid cytokine profile fol-
878 lowing anterior cruciate ligament reconstruction with patellar
879 tendon and hamstring tendon autografts. *Knee Surg Sports*
880 *Traumatol Arthrosc* 12:98–103 881
- 882 882

